Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 13;16(6):909-913.
doi: 10.1093/ckj/sfad045. eCollection 2023 Jun.

Searching in the maze: sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival

Laia Oliveras  1 , Núria Montero  1 , Josep M Cruzado  1   2   3
Affiliations
Editorial

Searching in the maze: sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival

Laia Oliveras et al. Clin Kidney J. .

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular and renal outcomes in chronic kidney disease patients with and without diabetes. Kidney transplant recipients have been excluded from landmark trials using SGLT2is and literature on safety and efficacy are scarce. Recent studies suggest that the SGLT2i use in kidney transplant recipients with diabetes is safe, paving the way to investigate whether SGLT2is could also reduce cardiovascular events and kidney function deterioration in kidney allograft recipients.

Keywords: diabetes; kidney transplant; sodium–glucose cotransporter-2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

J.M.C. is member of the CKJ editorial board. The other authors declare no conflicts of interest.

References

    1. van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 2022;18:294–306. 10.1038/s41581-022-00535-6 - DOI - PubMed
    1. Kidney Disease: Improving Global Outcomes Diabetes Work Group . KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022;102(5 Suppl):S1–127. https://pubmed.ncbi.nlm.nih.gov/36272764/ - PubMed
    1. Stegall MD, Cornell LD, Park WDet al. . Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury. Am J Transplant 2018;18:180–8. 10.1111/ajt.14431 - DOI - PubMed
    1. Jenssen TG. Efficacy and safety of sodium-glucose-transporter-2 inhibitors in kidney transplant patients. Curr Opin Nephrol Hypertens 2021;30:577–83. 10.1097/MNH.0000000000000749 - DOI - PubMed
    1. Sánchez-Fructoso AI, Raba AB, Deras EBet al. . Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicenter study. Clin Kidney J 2023;10.1093/ckj/sfad007 - DOI - PMC - PubMed

Publication types